Mild Clostridium difficile infection (CDI ... clinical deterioration and place on therapy immediately if this occurs. Treatment for an initial episode and a first recurrence of CDI: If oral ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Objective: To describe emergent therapies, such as rifaximin, nitazoxanide, intravenous immunoglobulin (IVIG), tinidazole, tolevamer, and the possible use of a vaccine, in Clostridium difficile ...

H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

New analyses extend data on beneficial effects of ibezapolstat on the gut microbiomeConfirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic ...

However, the overuse of antimicrobials has resulted in antimicrobial resistance (AMR) that has led to the emergence of ...

Infectious diseases were the leading causes of death on the first Labor Day, just ahead of a major epidemiological shift that brought both vaccines to fight these deadly ailments but also the rise ...

PPI use has been associated with an increased risk of enteric infections, most notably Clostridium difficile. The gut microbiome plays an important role in enteric infections, by resisting or ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...